Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
- Associated Conditions
- -
- Associated Therapies
- -
Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT00816543
- Locations
- 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00651742
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00652054
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00651833
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00652561
S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT00602745
- Locations
- 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00553696
- Locations
- 🇯🇵
Saku Central Hospital, GI Devision, Saku, Nagano, Japan
🇯🇵Aichi cancer center central hospital / Medical Oncology, Nagoya, Aichi, Japan
🇯🇵Shizuoka Cancer Center, Suntougun, Shizuoka, Japan
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
- Conditions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT00479076
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Japan Breast Cancer Research Network
- Target Recruit Count
- 142
- Registration Number
- NCT00438100
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
🇯🇵Kyushu Central Hospital, Fukuoka, Japan
🇯🇵Hirosaki University Hospital, Hirosaki, Japan
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Andrew Ko
- Target Recruit Count
- 21
- Registration Number
- NCT00429858
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.